DPM2

Last update 08 May 2025

Basic Info

Synonyms

Dolichol phosphate-mannose biosynthesis regulatory protein, Dolichol-phosphate mannose synthase subunit 2, dolichyl-phosphate mannosyltransferase subunit 2, regulatory

+ [4]

Introduction

Regulates the biosynthesis of dolichol phosphate-mannose (PubMed:10835346). Regulatory subunit of the dolichol-phosphate mannose (DPM) synthase complex; essential for the ER localization and stable expression of DPM1 (PubMed:10835346). Part of the glycosylphosphatidylinositol-N-acetylglucosaminyltransferase (GPI-GnT) complex that catalyzes the transfer of N-acetylglucosamine from UDP-N-acetylglucosamine to phosphatidylinositol and participates in the first step of GPI biosynthesis (PubMed:16162815). May act by regulating the GPI-GNT complex (PubMed:10944123).

100 Clinical Results associated with DPM2

100 Translational Medicine associated with DPM2

0 Patents (Medical) associated with DPM2

Literatures (Medical) associated with DPM2

01 Mar 2025·Environmental Toxicology

RETRACTION: DPM2 Serve as Novel Oncogene and Prognostic Marker Transactivated by ESR1 in Breast Cancer

Article

RETRACTION:

Lu,

Feng,

Zhou,

Xiao,

Yang,

Li,

Cai, and

Wang, “,” Environmental Toxicology39, no. (2024): 1737–1746, https://doi.org/10.1002/tox.24059.

The above article, published online on 05 December 2023, in Wiley Online Library (http://onlinelibrary.wiley.com/), has been retracted by agreement between the journal Editor‐in‐Chief, Paul B. Tchounwou; and Wiley Periodicals LLC. Following an investigation by the publisher, the parties have concluded that this article was accepted solely on the basis of a compromised peer review process. Therefore, the article must be retracted. The author Jie Wang disagrees with this decision. The other authors did not respond.

01 Mar 2024·Environmental Toxicology

RETRACTED: DPM2 serve as novel oncogene and prognostic marker transactivated by ESR1 in breast cancer

Article

Author: Lu, Jiahao ; Wang, Jie ; Zhou, Yiting ; Yang, Zean ; Li, Jiaxian ; Feng, Yuejiao ; Xiao, Zengyou ; Cai, Han

AbstractBreast cancer (BRCA) is the most common malignancies worldwide with increasing rate. Dolichol phosphate mannose synthase (DPMS) is a critical mannosyltransferase involved in the posttranslational modification of proteins. At present, there is limited knowledge regarding the function of DPMS in breast cancer. In this study, silica analysis in multiple datasets found that dolichyl‐phosphate mannosyltransferase subunit 2 (DPM2) is an unfavorable prognostic marker, suggesting its oncogenic role. Cell counting kit‐8 and apoptosis assays show that DPM2‐silenced cancer cells exhibit decreased growth potential and enhanced cell death rate. Further, transwell and wound healing assays show reduced invasion and migration capabilities in DPM2 knockdown groups, xenograft nude mice model demonstrated smaller tumor volume in DPM2 silenced BC cells. Then, the underlying downstream mechanism of DPM2 in BC was predicted and analyzed, highlighting classical tumorigenic pathways like JAK/STAT signaling pathway and oxidative phosphorylation activated in the cancer group. Finally, ChIP‐seq analysis, expression correlation analysis, inhibitor treatment, and dual luciferase assays show that DPM2 is transcriptionally activated by estrogen receptor1 (ESR1). The results show that high expression of DPM2 mRNA is significantly correlated with shorter overall survival (OS) and disease‐free survival (DFS) in breast cancer patients, and in vitro knockdown of DPM2 can significantly inhibit the malignant phenotypes of cells, including proliferation, invasion, migration, and apoptosis. These results suggest that DPM2 may play an important role in breast cancer. Altogether, we first uncovered the tumorigenic and prognostic role of DPM2 in breast cancer, cellular assays, and bioinformatics analysis highlighted DPM2 as oncogene via inhibited cancer‐related signaling pathways in breast cancer. Besides, DPM2 is transcriptionally activated by ESR1, the signaling axis of ESR1/DPM2 provides a new strategy for BC‐targeted therapy.

01 Jan 2023·Frontiers in genetics

Identification and characterization of a new variation in DPM2 gene in two Chinese siblings with mild intellectual impairment.

Article

Author: Li, Cheng ; Zhu, Hongmin ; He, Xuelian ; Hu, Juan ; Luo, Sukun ; Hu, Yanqiu ; Jiang, Jun ; Zhang, Lei ; Zhao, Peiwei ; Huang, Yufeng

Congenital disorders of glycosylation (CDGs) are a genetically heterogeneous group of metabolic disorders caused by abnormal protein or lipid glycosylation.DPM2 is one subunit of a heterotrimeric complex for dolichol-phosphatemannose synthase (DPMS), a key enzyme in glycosylation, and only four patients with DPM2-CDG have been reported.Whole-exome sequencing (WES) was performed in a Chinese family having two siblings with a mild form of DPM2-CDG with developmental delay, mild intellectual disability, hypotonia, and increased serum creatine kinase.Sanger sequencing was used to validate the variants identified in the siblings and their parents.In vitro functional study was performed.A homozygous mutation, c.197G>A (p.Gly66Glu) in exon 4 of DPM2 (NM_ 003863) was identified by whole exome sequencing (WES).In vitro functional anal. demonstrated that this variant increased the expression level of DPM2 protein and western blot revealed a significant decrease in ICAM1, a universal biomarker for hypoglycosylation in patients with CDG, suggesting abnormal N-linked glycosylation.We also reviewed the 4 previously reported patients carrying homozygous or compound heterozygous variants of DMP2 gene, and found that patients with variants within the region encoding the first domain had more severe clin. symptoms than those with variants within the second domain.However, the actual genotype-phenotype relationship needs more study.Overall, our study broadens the variant spectrum of DPM2 gene, attempts to explain the different phenotypes in patients with different DPM2 variants, and emphasizes the need of further functional studies to understand the underlying pathophysiol. of the phenotypic heterogeneity.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

DPM2

Basic Info

Related

Analysis